Mirati Therapeutics, Inc.·4

Jan 30, 5:56 PM ET

Mirati Therapeutics, Inc. 4

4 · Mirati Therapeutics, Inc. · Filed Jan 30, 2017

Insider Transaction Report

Form 4
Period: 2017-01-26
LEMASTERS CHRISTOPHER C.
EVP, Chief Business Officer
Transactions
  • Award

    Option Grant (Right to Buy)

    2017-01-26+11,25011,250 total
    Exercise: $5.40Exp: 2027-01-25Common Stock (11,250 underlying)
Footnotes (1)
  • [F1]1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT